Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of AK112 (Anti-PD-1 and VEGF Bi-specific Antibody) in the Treatment of Advanced Gynecological Carcinoma

NCT04870177 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT04870177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04870177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of AK112 (Anti-PD-1 and VEGF Bi-specific Antibody) in the Treatment of Advanced Gynecological Carcinoma
Lead sponsor
Akeso
Phase
Phase 2
Overall status
Completed
Start date
April 9, 2021
Completion date
May 10, 2024
Enrollment
53 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer metastatic, cervical neoplasm, endometrial neoplasms, gynecologic cancer, ovarian neoplasms